We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Harnessing the Metabolism of Oncogenic Signaling for More Effective Anticancer Therapy

Harnessing the Metabolism of Oncogenic Signaling for More Effective Anticancer Therapy content piece image

Metabolic rewiring has long been overlooked as a significant pathogenic mechanism in cancer. My group’s work provides indubitable evidence that the reciprocal relationship between changes in metabolism and oncogenic signaling creates dependencies that promise future targets for clinical investigation.

This webinar will discuss the use of cutting-edge technologies, to track the metabolism of breast cancer tumors and preclinical models, for the identification of metabolic determinants that guide the response to anticancer therapies. In this context, it will assist with gaining insight into how the metabolism of a cancer cell, driven by oncogenic mutation in PIK3CA, affects its proliferation beyond a cell-autonomous manner and contributes to evading immune surveillance.

In the longer term, this knowledge exposes weaknesses in the tumor’s armor and unveils more effective therapeutic strategies where the combination of dietary interventions and metabolic targets helps circumvent drug resistance, restores tumoral immune cell infiltration and slows down tumor growth.

Attend this webinar to explore:

  • The use of cutting-edge technologies to track tumor metabolism
  • Crosstalk between oncogenic signaling and metabolic rewiring
  • The role of dietary interventions in anticancer therapy response
Dr George Poulogiannis
Dr George Poulogiannis
Team Leader in the Division of Cancer Biology, The Institute of Cancer Research, London